Degarelix

Generic Name: Degarelix

Brand Names: Firmagon, Degarelix Accord

Drug Type: Small Molecule

Chemical Formula: C_₈₂H_₁₀₃ClN_₁₈O_₁₆

CAS Number: 214766-78-6

Unique Ingredient Identifier: SX0XJI3A11

Background: Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

Indication: Degaralix is used for the management of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Clinical Trials

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Phase 3

Recruiting

Conditions: Biochemically Recurrent Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Procedure: Computed Tomography
Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Apalutamide
Drug: Degarelix
Radiation: External Beam Radiation Therapy
Other: Fluciclovine F18
Drug: Goserelin Acetate
Drug: Leuprolide Acetate
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Intensity-Modulated Proton Therapy
Other: Quality-of-Life Assessment
Radiation: Intensity-Modulated Radiation Therapy
Other: Questionnaire Administration
Drug: Relugolix
Drug: Triptorelin
Radiation: Stereotactic Body Radiation Therapy
Radiation: Volume Modulated Arc Therapy

First Posted Date: 2020-06-09

Last Posted Date: 2024-11-05

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 804

Registration Number: NCT04423211

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 299 locations

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization

Phase 2

Completed

Conditions: COVID-19

Interventions: Other: Saline
Drug: Degarelix

First Posted Date: 2020-05-21

Last Posted Date: 2022-06-06

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 96

Registration Number: NCT04397718

Locations: 🇺🇸
St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States
🇺🇸
Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States
🇺🇸
Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn, New York, United States

and more 11 locations

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

Phase 2

Completed

Conditions: Prostate Adenocarcinoma

Interventions: Drug: Firmagon

First Posted Date: 2020-05-18

Last Posted Date: 2025-02-18

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 57

Registration Number: NCT04391556

Locations: 🇫🇷
Chu Gabriel Montpied, Clermont-Ferrand, France
🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre Hospitalier de Grenoble Hôpital Nord Michallon, La Tronche, France

and more 3 locations

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

Early Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Drug: BMS-986218 and Degarelix

First Posted Date: 2020-03-10

Last Posted Date: 2024-07-09

Lead Sponsor: Columbia University

Target Recruit Count: 26

Registration Number: NCT04301414

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer

Recruiting

Conditions: Bladder Cancer
Quality of Life
Radiation Therapy Complication

Interventions: Drug: Degarelix

First Posted Date: 2020-02-25

Last Posted Date: 2022-08-08

Lead Sponsor: Aarhus University Hospital

Target Recruit Count: 60

Registration Number: NCT04282876

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Phase 4

Conditions: Prostatic Neoplasms

Interventions: Drug: Leuprorelin
Drug: Goserelin
Drug: Triptorelin
Drug: Degarelix
Drug: Bicalutamide
Drug: Flutamide
Drug: Maximum androgen blockade

First Posted Date: 2020-01-30

Last Posted Date: 2021-07-29

Lead Sponsor: Wonju Severance Christian Hospital

Target Recruit Count: 164

Registration Number: NCT04248621

Locations: 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷
Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷
Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of

and more 7 locations